282 related articles for article (PubMed ID: 33524948)
1. Safety and interim survival data after intracranial administration of M032, a genetically engineered oncolytic HSV-1 expressing IL-12, in pet dogs with sporadic gliomas.
Omar NB; Bentley RT; Crossman DK; Foote JB; Koehler JW; Markert JM; Platt SR; Rissi DR; Shores A; Sorjonen D; Yanke AB; Gillespie GY; Chambers MR
Neurosurg Focus; 2021 Feb; 50(2):E5. PubMed ID: 33524948
[TBL] [Abstract][Full Text] [Related]
2. The One Health Consortium: Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Combination With a Checkpoint Inhibitor in Canine Patients With Sporadic High Grade Gliomas.
Chambers MR; Bentley RT; Crossman DK; Foote JB; Koehler JW; Markert JM; Omar NB; Platt SR; Self DM; Shores A; Sorjonen DC; Waters AM; Yanke AB; Gillespie GY
Front Surg; 2020; 7():59. PubMed ID: 33005623
[TBL] [Abstract][Full Text] [Related]
3. Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma.
Patel DM; Foreman PM; Nabors LB; Riley KO; Gillespie GY; Markert JM
Hum Gene Ther Clin Dev; 2016 Jun; 27(2):69-78. PubMed ID: 27314913
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the safety and biodistribution of M032, an attenuated herpes simplex virus type 1 expressing hIL-12, after intracerebral administration to aotus nonhuman primates.
Roth JC; Cassady KA; Cody JJ; Parker JN; Price KH; Coleman JM; Peggins JO; Noker PE; Powers NW; Grimes SD; Carroll SL; Gillespie GY; Whitley RJ; Markert JM
Hum Gene Ther Clin Dev; 2014 Mar; 25(1):16-27. PubMed ID: 24649838
[TBL] [Abstract][Full Text] [Related]
5. Systemic cellular viroimmunotherapy for canine high-grade gliomas.
Cloquell A; Mateo I; Gambera S; Pumarola M; Alemany R; García-Castro J; Perisé-Barrios AJ
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36600663
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of immunologic parameters in canine glioma patients treated with an oncolytic herpes virus.
Chambers MR; Foote JB; Bentley RT; Botta D; Crossman DK; Della Manna DL; Estevez-Ordonez D; Koehler JW; Langford CP; Miller MA; Markert JM; Olivier AK; Omar NB; Platt SR; Rissi DR; Shores A; Sorjonen DC; Yang ES; Yanke AB; Gillespie GY
J Transl Genet Genom; 2021; 5(4):423-442. PubMed ID: 35342877
[TBL] [Abstract][Full Text] [Related]
7. Rationale and Design of a Phase 1 Clinical Trial to Evaluate HSV G207 Alone or with a Single Radiation Dose in Children with Progressive or Recurrent Malignant Supratentorial Brain Tumors.
Waters AM; Johnston JM; Reddy AT; Fiveash J; Madan-Swain A; Kachurak K; Bag AK; Gillespie GY; Markert JM; Friedman GK
Hum Gene Ther Clin Dev; 2017 Mar; 28(1):7-16. PubMed ID: 28319448
[TBL] [Abstract][Full Text] [Related]
8. Oncolytic viruses as treatment for adult and pediatric high-grade gliomas: On the way to clinical success.
Hervás-Corpión I; Alonso MM
Int Rev Cell Mol Biol; 2023; 379():169-188. PubMed ID: 37541723
[TBL] [Abstract][Full Text] [Related]
9. Active immunotherapy: oncolytic virus therapy using HSV-1.
Todo T
Adv Exp Med Biol; 2012; 746():178-86. PubMed ID: 22639168
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas.
Zeng J; Li X; Sander M; Zhang H; Yan G; Lin Y
Front Immunol; 2021; 12():721830. PubMed ID: 34675919
[TBL] [Abstract][Full Text] [Related]
11. Promises of oncolytic viral therapy for adult and children with brain glioma.
Patiño-García A; Alonso MM; Gállego Pérez-Larraya J
Curr Opin Oncol; 2023 Nov; 35(6):529-535. PubMed ID: 37820087
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic virus therapy using genetically engineered herpes simplex viruses.
Todo T
Front Biosci; 2008 Jan; 13():2060-4. PubMed ID: 17981691
[TBL] [Abstract][Full Text] [Related]
13. Advances and potential pitfalls of oncolytic viruses expressing immunomodulatory transgene therapy for malignant gliomas.
Zhang Q; Liu F
Cell Death Dis; 2020 Jun; 11(6):485. PubMed ID: 32587256
[TBL] [Abstract][Full Text] [Related]
14. [Oncolytic virus therapy for malignant brain tumors].
Ino Y; Todo T
Brain Nerve; 2009 Jul; 61(7):815-22. PubMed ID: 19618859
[TBL] [Abstract][Full Text] [Related]
15. Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins.
Andreansky S; He B; van Cott J; McGhee J; Markert JM; Gillespie GY; Roizman B; Whitley RJ
Gene Ther; 1998 Jan; 5(1):121-30. PubMed ID: 9536273
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic measles virus strains in the treatment of gliomas.
Allen C; Paraskevakou G; Liu C; Iankov ID; Msaouel P; Zollman P; Myers R; Peng KW; Russell SJ; Galanis E
Expert Opin Biol Ther; 2008 Feb; 8(2):213-20. PubMed ID: 18194077
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic HSV-1 G207 Immunovirotherapy for Pediatric High-Grade Gliomas.
Friedman GK; Johnston JM; Bag AK; Bernstock JD; Li R; Aban I; Kachurak K; Nan L; Kang KD; Totsch S; Schlappi C; Martin AM; Pastakia D; McNall-Knapp R; Farouk Sait S; Khakoo Y; Karajannis MA; Woodling K; Palmer JD; Osorio DS; Leonard J; Abdelbaki MS; Madan-Swain A; Atkinson TP; Whitley RJ; Fiveash JB; Markert JM; Gillespie GY
N Engl J Med; 2021 Apr; 384(17):1613-1622. PubMed ID: 33838625
[TBL] [Abstract][Full Text] [Related]
18. Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial.
Fares J; Ahmed AU; Ulasov IV; Sonabend AM; Miska J; Lee-Chang C; Balyasnikova IV; Chandler JP; Portnow J; Tate MC; Kumthekar P; Lukas RV; Grimm SA; Adams AK; Hébert CD; Strong TV; Amidei C; Arrieta VA; Zannikou M; Horbinski C; Zhang H; Burdett KB; Curiel DT; Sachdev S; Aboody KS; Stupp R; Lesniak MS
Lancet Oncol; 2021 Aug; 22(8):1103-1114. PubMed ID: 34214495
[TBL] [Abstract][Full Text] [Related]
19. [Oncolytic viruses for therapy of malignant glioma].
Sosnovtceva AO; Grinenko NF; Lipatova AV; Chumakov PM; Chekhonin VP
Biomed Khim; 2016 May; 62(4):376-90. PubMed ID: 27562991
[TBL] [Abstract][Full Text] [Related]
20. Expression of FMS-like tyrosine kinase 3 ligand by oncolytic herpes simplex virus type I prolongs survival in mice bearing established syngeneic intracranial malignant glioma.
Barnard Z; Wakimoto H; Zaupa C; Patel AP; Klehm J; Martuza RL; Rabkin SD; Curry WT
Neurosurgery; 2012 Sep; 71(3):741-8; discussion 748. PubMed ID: 22653387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
